ストックスクリーナーアプリを入手
0.2653
0.30%
-0.0013
前日終値:
$0.2666
開ける：
$0.284
24時間の取引高:
401.87K
Relative Volume:
0.25
時価総額：
$62.81M
収益：
$175.04M
当期純損益:
$-44.52M
株価収益率:
-1.4739
EPS:
-0.18
ネットキャッシュフロー:
$-56.05M
1週間 パフォーマンス:
+11.59%
1か月 パフォーマンス:
+6.32%
6か月 パフォーマンス:
-63.96%
1年 パフォーマンス:
-74.92%
1日の値動き範囲:
$0.2608
$0.284
1週間の範囲:
$0.2394
$0.2977
52週間の値動き範囲:
$0.1951
$1.48
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
名前
Adaptimmune Therapeutics Plc Adr
セクター
電話
44 1235 430000
住所
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
ADAP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.2655 | 62.81M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.67 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.60 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
610.98 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.64 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
246.35 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Outperform |
| 2023-03-24 | 開始されました | Bryan Garnier | Buy |
| 2023-01-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-11-09 | アップグレード | Mizuho | Neutral → Buy |
| 2021-05-28 | 開始されました | Barclays | Underweight |
| 2020-04-22 | 開始されました | Mizuho | Neutral |
| 2019-08-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-05-31 | 開始されました | ROTH Capital | Buy |
| 2019-05-30 | 再開されました | Citigroup | Buy |
| 2019-05-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | 開始されました | Wells Fargo | Market Perform |
| 2016-10-24 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | 開始されました | Raymond James | Outperform |
| 2016-02-25 | 開始されました | Citigroup | Buy |
| 2015-06-01 | 開始されました | BofA/Merrill | Neutral |
| 2015-06-01 | 開始されました | Guggenheim | Buy |
| 2015-06-01 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Adaptimmune Therapeutics Plc Adr (ADAP) 最新ニュース
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com
How should investors view Lazard Inc (LAZ)? - uspostnews.com
Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com
It would be worthwhile to take a closer look at Quantum Corp (QMCO) - uspostnews.com
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com
Adaptimmune Therapeutics Amends Loan Agreement By Investing.com - Investing.com India
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com
Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire
LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.
Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register
Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily
Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily
Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily
A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily
Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex
Following A 4.11% Weekly Incline, Is It Still A Buy For Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)? - Marketing Sentinel
Should Outset Medical Inc (NASDAQ: OM) Rally After -544.44% Drop From High? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Stock Falling -5.24% Over A Month – Any Room For Its Value To Rise? – Marketing Sentinel - Marketing Sentinel
BioVie Inc (NASDAQ: BIVI): How Can A Stock Be Down -4.00% Year To Date, But Still Loser - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: A Closer Look at the Moving Averages - The News Heater
SM Energy Co (SM): A Technical Analysis - The News Heater
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025 - Newsfile
Adaptimmune Therapeutics Plc ADR (ADAP)’s stock price in review: A technical analysis - US Post News
Quarterly Snapshot: Quick and Current Ratios for Adaptimmune Therapeutics Plc ADR (ADAP) - The Dwinnex
Adaptimmune therapeutics COO sells shares worth $3,243 - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock By Investing.com - Investing.com South Africa
Adaptimmune therapeutics' chief medical officer sells $3,243 in stock - Investing.com India
Adaptimmune therapeutics COO sells shares worth $3,243 By Investing.com - Investing.com South Africa
Adaptimmune therapeutics COO William Bertrand sells $11,360 in shares - Investing.com India
Adaptimmune therapeutics' chief medical officer sells $12,920 in shares - Investing.com
Adaptimmune's chief commercial officer sells $7,467 in shares - Investing.com
Adaptimmune therapeutics CEO Adrian Rawcliffe sells shares worth $34,639 - Investing.com
AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register
These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock Is - Stocks Register
What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register
Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register
Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register
Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register
Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register
Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com
Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com
Adaptimmune Therapeutics Plc Adr (ADAP) 財務データ
収益
当期純利益
現金流量
EPS
Adaptimmune Therapeutics Plc Adr (ADAP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lunger John | Chief Patient Supply Officer |
Jan 17 '25 |
Sale |
0.58 |
5,584 |
3,243 |
7,510 |
| Bertrand William C JR | Chief Operating Officer |
Jan 17 '25 |
Sale |
0.58 |
5,584 |
3,243 |
7,510 |
| Rawcliffe Adrian | Chief Executive Officer |
Jan 17 '25 |
Sale |
0.58 |
30,601 |
17,773 |
44,327 |
0.63%
大文字化:
|
ボリューム (24 時間):